Faster, faster.

A phase 2 trial published last week in JCO reports outcomes for post-mastectomy radiation of 3.33 Gy x 11 fractions +/- 3.33 Gy x 4 scar boost. And get this: regional nodes were included, although internal mammary coverage was at the discretion of the treating physician. Grade 2 skin toxicity was 18% and there were no grade ≥3 toxicities. Most complications were related to reconstruction, and most of those were from infection. The same group has reported this regimen in the post-lumpectomy setting with slightly more skin toxicity and fibrosis. Notwithstanding missing details on internal mammary coverage and lung/heart dosimetry, this could represent an even more convenient breast radiation regimen. Canadians, look out.